GSK Gets FDA Approval for New Jemperli Use With Chemo

US regulators have cleared GSK Plc’s Jemperli drug in combination with chemotherapy as a frontline treatment for a particular type of endometrial cancer, boosting the drug’s blockbuster potential, according to a company press release.

European and US regulators greenlit the use of Jemperli in April 2021 and Monday’s expanded approval represents the first new frontline treatment option in decades for this type of cancer.

The US Food and Drug Administration didn’t immediately respond to comment.

The approval comes after a recent study found the drug, when combined with chemotherapy, reduced disease progression and the risk of death in ...